What did @realdrbae actually say?
A board-certified plastic surgeon with 1.6 million views claimed that stopping semaglutide or tirzepatide leads to weight regain "even though you're sticking extremely to a diet and exercise program." He also said diet and exercise alone are no longer "the answer" for people who struggle with their weight, and that staying on low-dose GLP-1 medications indefinitely, "one or two injections a month," can maintain weight loss long-term.
The core message: obesity is a chronic condition that likely requires chronic medication, and stopping these drugs means the weight comes back regardless of lifestyle effort. That framing is not wrong. But some of the specifics deserve scrutiny.
Does the science back this up?
On the main point, yes, the data are pretty clear and consistent. Weight regain after stopping GLP-1 receptor agonists is well-documented and substantial.
The landmark STEP 1 Extension trial (Wilding et al., 2022, Diabetes, Obesity and Metabolism) followed participants for 52 weeks after stopping semaglutide 2.4 mg. On average, they regained about two-thirds of their lost weight within a year. Cardiometabolic improvements largely reversed too. A similar pattern appeared with tirzepatide in the SURMOUNT-4 trial (Aronne et al., 2024, JAMA), where participants who switched from tirzepatide to placebo regained roughly half their lost weight over 52 weeks, while those who continued lost more.
The biology explains it. GLP-1 agonists suppress appetite partly by acting on hypothalamic circuits. When you remove the drug, those appetite-suppressing signals drop, and the body's energy-balance set point reasserts itself. Lifestyle changes alone rarely override that system in people with obesity, which is why the creator's skepticism toward "diet and exercise" as a standalone solution has genuine scientific backing.
What did they get wrong (or right)?
They got the big picture right. Regain after stopping is real, consistent, and not a personal failure. Credit where it is due.
But the claim that patients regain weight "even though they're sticking extremely to a diet and exercise program" is presented as a clinical observation from his practice, not a controlled finding. That framing is plausible given what we know about biology, but it is anecdotal. Adherence to diet and exercise is notoriously hard to verify, and confirmation bias in clinical observation is real.
The dosing suggestion, "one or two injections a month," is the part that raises flags. Semaglutide and tirzepatide are approved for weekly subcutaneous injection. No peer-reviewed data currently supports a monthly maintenance dosing schedule as effective for sustained weight control. The SURMOUNT-4 and STEP 5 trials used standard weekly dosing. Suggesting a non-standard frequency on a 1.6-million-view platform, even casually, is irresponsible without evidence. Patients should not adjust injection frequency based on a TikTok video.
What should you actually know?
Weight regain after stopping GLP-1 medications is the norm, not the exception. This is not a character flaw. It reflects how these drugs interact with the body's long-term energy regulation systems, and how persistent those systems are once the medication is gone.
The clinical implication, supported by data, is that obesity functions more like a chronic condition than an acute one, and treatment may need to be long-term. That does not automatically mean maximum doses forever. Dose reduction strategies are being studied, and some patients do maintain weight at lower doses. But the specific claim about monthly injections is not evidence-based at this time.
If you are considering stopping a GLP-1 medication or reducing your dose, that conversation belongs with the prescribing provider, not a TikTok comment section. Transitions off these medications should involve a plan, not a cold stop.
- Weight regain after GLP-1 discontinuation averages 50-67% of lost weight within 52 weeks across major trials.
- Continuing the medication remains the most effective strategy for maintaining weight loss based on current evidence.
- Monthly dosing as a maintenance strategy is not approved or supported by current clinical trial data.
- Long-term use of these medications is considered safe for most patients based on multi-year trial data, but requires ongoing clinical monitoring.